Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COYA NASDAQ:HLVX NASDAQ:MIRA NASDAQ:ONCY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOYACoya Therapeutics$5.67-0.2%$6.24$4.65▼$10.24$94.86M0.2678,398 shs156,169 shsHLVXHilleVax$2.09-0.5%$2.09$1.34▼$2.17$104.79M0.77394,760 shs2.80 million shsMIRAMIRA Pharmaceuticals$1.31-5.1%$1.50$0.73▼$2.56$24.98M1.751.07 million shs2.66 million shsONCYOncolytics Biotech$1.27+2.4%$1.09$0.33▼$1.53$127.46M1.191.02 million shs1.38 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOYACoya Therapeutics-6.12%-10.83%-7.64%+6.77%-11.25%HLVXHilleVax+0.48%+0.48%+0.96%+13.51%+14.75%MIRAMIRA Pharmaceuticals-4.83%0.00%-8.00%+7.81%+2.22%ONCYOncolytics Biotech-3.13%-3.13%+14.81%+85.60%+29.71%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOYACoya Therapeutics$5.67-0.2%$6.24$4.65▼$10.24$94.86M0.2678,398 shs156,169 shsHLVXHilleVax$2.09-0.5%$2.09$1.34▼$2.17$104.79M0.77394,760 shs2.80 million shsMIRAMIRA Pharmaceuticals$1.31-5.1%$1.50$0.73▼$2.56$24.98M1.751.07 million shs2.66 million shsONCYOncolytics Biotech$1.27+2.4%$1.09$0.33▼$1.53$127.46M1.191.02 million shs1.38 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOYACoya Therapeutics-6.12%-10.83%-7.64%+6.77%-11.25%HLVXHilleVax+0.48%+0.48%+0.96%+13.51%+14.75%MIRAMIRA Pharmaceuticals-4.83%0.00%-8.00%+7.81%+2.22%ONCYOncolytics Biotech-3.13%-3.13%+14.81%+85.60%+29.71%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOYACoya Therapeutics 3.00Buy$16.50191.01% UpsideHLVXHilleVax 2.00Hold$2.00-4.31% DownsideMIRAMIRA Pharmaceuticals 3.50Strong Buy$17.001,197.71% UpsideONCYOncolytics Biotech 2.80Moderate Buy$5.00293.70% UpsideCurrent Analyst Ratings BreakdownLatest MIRA, ONCY, HLVX, and COYA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/4/2025COYACoya TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$18.008/25/2025COYACoya TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$18.008/25/2025COYACoya TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$18.008/13/2025COYACoya TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$18.008/13/2025COYACoya TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.008/13/2025ONCYOncolytics BiotechLake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$7.008/8/2025HLVXHilleVaxZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold7/24/2025COYACoya TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$18.007/9/2025COYACoya TherapeuticsLake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$16.007/1/2025COYACoya TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOYACoya Therapeutics$3.55M26.72N/AN/A$2.37 per share2.39HLVXHilleVaxN/AN/AN/AN/A$3.10 per shareN/AMIRAMIRA PharmaceuticalsN/AN/AN/AN/A$0.13 per shareN/AONCYOncolytics BiotechN/AN/AN/AN/A$0.05 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOYACoya Therapeutics-$14.88M-$1.24N/AN/AN/AN/A-61.05%-53.61%11/5/2025 (Estimated)HLVXHilleVax-$147.27M-$1.43N/AN/AN/AN/A-34.29%-28.50%11/6/2025 (Estimated)MIRAMIRA Pharmaceuticals-$7.85M-$0.49N/AN/AN/AN/A-406.70%-328.44%11/11/2025 (Estimated)ONCYOncolytics Biotech-$23.14M-$0.27N/AN/AN/AN/A-438.11%-143.90%11/11/2025 (Estimated)Latest MIRA, ONCY, HLVX, and COYA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025MIRAMIRA Pharmaceuticals-$0.11-$0.09+$0.02-$0.09N/AN/A8/12/2025Q2 2025COYACoya Therapeutics-$0.22-$0.36-$0.14-$0.36$0.78 million$0.16 million8/8/2025Q2 2025ONCYOncolytics Biotech-$0.11-$0.05+$0.06-$0.05N/AN/A8/6/2025Q2 2025HLVXHilleVax-$0.14-$0.11+$0.03-$0.11N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOYACoya TherapeuticsN/AN/AN/AN/AN/AHLVXHilleVaxN/AN/AN/AN/AN/AMIRAMIRA PharmaceuticalsN/AN/AN/AN/AN/AONCYOncolytics BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOYACoya TherapeuticsN/A7.437.43HLVXHilleVaxN/A26.3926.39MIRAMIRA PharmaceuticalsN/A2.802.80ONCYOncolytics BiotechN/A2.882.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOYACoya Therapeutics39.75%HLVXHilleVax86.42%MIRAMIRA Pharmaceuticals35.16%ONCYOncolytics Biotech6.82%Insider OwnershipCompanyInsider OwnershipCOYACoya Therapeutics12.00%HLVXHilleVax24.90%MIRAMIRA Pharmaceuticals6.65%ONCYOncolytics Biotech0.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOYACoya Therapeutics616.73 million14.72 millionNot OptionableHLVXHilleVax2050.14 million37.66 millionNot OptionableMIRAMIRA Pharmaceuticals219.07 million17.80 millionNot OptionableONCYOncolytics Biotech30100.36 million100.26 millionNot OptionableMIRA, ONCY, HLVX, and COYA HeadlinesRecent News About These CompaniesOncolytics Biotech Expands GOBLET Study to U.S., Shows Promising ResultsSeptember 16 at 11:22 AM | msn.comOncolytics Biotech® Provides Update on GOBLET Study Progress and U.S. Site ExpansionSeptember 16 at 7:00 AM | prnewswire.comLake Street Keeps Their Buy Rating on Oncolytics Biotech (ONCY)September 10, 2025 | theglobeandmail.comOncolytics Biotech (ONCY) Receives a Hold from JonesTradingSeptember 10, 2025 | theglobeandmail.comBreakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape MarketSeptember 9, 2025 | newswire.caOncolytics Biotech Reports Promising Results in Metastatic Colorectal Cancer StudiesSeptember 8, 2025 | tipranks.comOncolytics Biotech® Highlights Strong Efficacy and Translational Data in Metastatic Colorectal Cancer; Will Advance Regulatory Pathway DiscussionsSeptember 8, 2025 | prnewswire.comOncolytics Biotech® Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal TumorsSeptember 2, 2025 | prnewswire.comCancer Treatment Revolution Drives $903B Market as New Therapies Gain MomentumAugust 28, 2025 | baystreet.caOncolytics Biotech® Announces Upcoming Investor Conferences in SeptemberAugust 28, 2025 | prnewswire.comHere's Why We're Watching Oncolytics Biotech's (NASDAQ:ONCY) Cash Burn SituationAugust 27, 2025 | finance.yahoo.comOncolytics Biotech Inc. (NASDAQ:ONCY) Receives Consensus Recommendation of "Moderate Buy" from AnalystsAugust 26, 2025 | marketbeat.comOncolytics Biotech (NASDAQ:ONCY) Raised to Hold at Wall Street ZenAugust 17, 2025 | marketbeat.comLake Street Initiates Coverage of Oncolytics Biotech (ONCY) with Buy RecommendationAugust 14, 2025 | msn.comOncolytics Biotech Inc.: Oncolytics Biotech Announces Voting Results from the Annual General Meeting of ShareholdersAugust 12, 2025 | finanznachrichten.deOncolytics Biotech® Announces Voting Results from the Annual General Meeting of ShareholdersAugust 11, 2025 | prnewswire.comJonesTrading Remains a Hold on Oncolytics Biotech (ONCY)August 10, 2025 | theglobeandmail.comOncolytics Biotech Inc.: Oncolytics Biotech Reports Second Quarter Financial Results and Details Clinical Program Plans for PelareorepAugust 8, 2025 | finanznachrichten.deOncolytics Biotech Inc.: Oncolytics Biotech Announces Voluntary Delisting from the Toronto Stock ExchangeAugust 8, 2025 | finanznachrichten.deOncolytics Biotech Files SEC Report Incorporating Information CircularAugust 8, 2025 | tipranks.comOncolytics Biotech Reports Reduced Losses in Q2 2025 Financial UpdateAugust 8, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMIRA, ONCY, HLVX, and COYA Company DescriptionsCoya Therapeutics NASDAQ:COYA$5.67 -0.01 (-0.18%) Closing price 04:00 PM EasternExtended Trading$5.70 +0.04 (+0.62%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.HilleVax NASDAQ:HLVX$2.09 -0.01 (-0.48%) Closing price 04:00 PM EasternExtended Trading$2.10 +0.01 (+0.48%) As of 06:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.MIRA Pharmaceuticals NASDAQ:MIRA$1.31 -0.07 (-5.07%) Closing price 04:00 PM EasternExtended Trading$1.30 -0.01 (-0.76%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.Oncolytics Biotech NASDAQ:ONCY$1.27 +0.03 (+2.42%) Closing price 04:00 PM EasternExtended Trading$1.29 +0.02 (+1.57%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
